Further support for focusing on CD16 to create cancer immunotherapies comes from several avenues: the development of a high-affinity, non-cleavable CD16 that was incorporated into pluripotent stem cell-derived NK cells for improved antitumor capabilities when combined with mAbs69, utilization of CD56dimCD16+ NK cells to improve dendritic cell vaccination response70, and the bi- and tri-specific killer engagers (BiKEs and TriKEs) against tumor-specific antigens to enhance NK cell-mediated tumor rejection71–74. The gene discussed is FCGR3B; the disease is neoplasm.